Moitreyee Chatterjee-Kishore has more than 20 years of biopharmaceutical experience spanning leadership and drug development. She currently serves as Head of Development, Immuno-Oncology and Cancer Cell Therapy at Astellas, with responsibility for driving the end-to-end development of Astellas’ most promising immuno-oncology and cancer cell therapy programs.

Before joining Astellas, Moitreyee was Head of Research and Early Development R&D Strategy and Planning at Bristol Myers Squibb and held several senior development and early pipeline leadership roles at Janssen, AbbVie and Wyeth. Prior to this, she served as a research scientist at research institutions including the Cleveland Clinic Foundation, Ohio, and Friedrich Miescher Institute for Biomedical Research, Basel.

She has led programs from discovery through late phase clinical development across a broad range of modalities, platforms and therapy areas with a strong focus in oncology and immuno-oncology.

Moitreyee holds a Ph.D. in Medical Genetics from the Sanjay Gandhi Post Graduate Institute of Medical Sciences, India, and an M.B.A from Purdue University Daniels School of Business, Indiana.